Literature DB >> 29677512

Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains.

Lin Guo1, Hong Joo Kim2, Hejia Wang1, John Monaghan3, Fernande Freyermuth4, Julie C Sung1, Kevin O'Donovan2, Charlotte M Fare1, Zamia Diaz1, Nikita Singh1, Zi Chao Zhang5, Maura Coughlin2, Elizabeth A Sweeny1, Morgan E DeSantis1, Meredith E Jackrel1, Christopher B Rodell6, Jason A Burdick6, Oliver D King7, Aaron D Gitler8, Clotilde Lagier-Tourenne4, Udai Bhan Pandey3, Yuh Min Chook9, J Paul Taylor10, James Shorter11.   

Abstract

RNA-binding proteins (RBPs) with prion-like domains (PrLDs) phase transition to functional liquids, which can mature into aberrant hydrogels composed of pathological fibrils that underpin fatal neurodegenerative disorders. Several nuclear RBPs with PrLDs, including TDP-43, FUS, hnRNPA1, and hnRNPA2, mislocalize to cytoplasmic inclusions in neurodegenerative disorders, and mutations in their PrLDs can accelerate fibrillization and cause disease. Here, we establish that nuclear-import receptors (NIRs) specifically chaperone and potently disaggregate wild-type and disease-linked RBPs bearing a NLS. Karyopherin-β2 (also called Transportin-1) engages PY-NLSs to inhibit and reverse FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2 fibrillization, whereas Importin-α plus Karyopherin-β1 prevent and reverse TDP-43 fibrillization. Remarkably, Karyopherin-β2 dissolves phase-separated liquids and aberrant fibrillar hydrogels formed by FUS and hnRNPA1. In vivo, Karyopherin-β2 prevents RBPs with PY-NLSs accumulating in stress granules, restores nuclear RBP localization and function, and rescues degeneration caused by disease-linked FUS and hnRNPA2. Thus, NIRs therapeutically restore RBP homeostasis and mitigate neurodegeneration.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; FTD; FUS; Karyopherin-β2; Nuclear-important receptor; TDP-43; disaggregase; hnRNPA1; neurodegeneration; phase transition

Mesh:

Substances:

Year:  2018        PMID: 29677512      PMCID: PMC5911940          DOI: 10.1016/j.cell.2018.03.002

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  38 in total

1.  Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS).

Authors:  Zi Chao Zhang; Yuh Min Chook
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

Review 3.  RNA-binding proteins with prion-like domains in health and disease.

Authors:  Alice Ford Harrison; James Shorter
Journal:  Biochem J       Date:  2017-04-07       Impact factor: 3.857

4.  Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.

Authors:  Meredith E Jackrel; Morgan E DeSantis; Bryan A Martinez; Laura M Castellano; Rachel M Stewart; Kim A Caldwell; Guy A Caldwell; James Shorter
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

5.  RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.

Authors:  J Gavin Daigle; Nicholas A Lanson; Rebecca B Smith; Ian Casci; Astha Maltare; John Monaghan; Charles D Nichols; Dmitri Kryndushkin; Frank Shewmaker; Udai Bhan Pandey
Journal:  Hum Mol Genet       Date:  2012-12-20       Impact factor: 6.150

6.  Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration.

Authors:  Agnes L Nishimura; Vera Zupunski; Claire Troakes; Claudia Kathe; Pietro Fratta; Michael Howell; Jean-Marc Gallo; Tibor Hortobágyi; Christopher E Shaw; Boris Rogelj
Journal:  Brain       Date:  2010-05-14       Impact factor: 13.501

7.  Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization.

Authors:  Amandine Molliex; Jamshid Temirov; Jihun Lee; Maura Coughlin; Anderson P Kanagaraj; Hong Joo Kim; Tanja Mittag; J Paul Taylor
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

8.  A yeast model of FUS/TLS-dependent cytotoxicity.

Authors:  Shulin Ju; Daniel F Tardiff; Haesun Han; Kanneganti Divya; Quan Zhong; Lynne E Maquat; Daryl A Bosco; Lawrence J Hayward; Robert H Brown; Susan Lindquist; Dagmar Ringe; Gregory A Petsko
Journal:  PLoS Biol       Date:  2011-04-26       Impact factor: 8.029

9.  Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins.

Authors:  Yuan Lin; David S W Protter; Michael K Rosen; Roy Parker
Journal:  Mol Cell       Date:  2015-09-24       Impact factor: 17.970

10.  ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function.

Authors:  Tetsuro Murakami; Seema Qamar; Julie Qiaojin Lin; Gabriele S Kaminski Schierle; Eric Rees; Akinori Miyashita; Ana R Costa; Roger B Dodd; Fiona T S Chan; Claire H Michel; Deborah Kronenberg-Versteeg; Yi Li; Seung-Pil Yang; Yosuke Wakutani; William Meadows; Rodylyn Rose Ferry; Liang Dong; Gian Gaetano Tartaglia; Giorgio Favrin; Wen-Lang Lin; Dennis W Dickson; Mei Zhen; David Ron; Gerold Schmitt-Ulms; Paul E Fraser; Neil A Shneider; Christine Holt; Michele Vendruscolo; Clemens F Kaminski; Peter St George-Hyslop
Journal:  Neuron       Date:  2015-10-29       Impact factor: 17.173

View more
  148 in total

1.  The SH3 domain of Fyn kinase interacts with and induces liquid-liquid phase separation of the low-complexity domain of hnRNPA2.

Authors:  Joshua Amaya; Veronica H Ryan; Nicolas L Fawzi
Journal:  J Biol Chem       Date:  2018-11-05       Impact factor: 5.157

Review 2.  New pathologic mechanisms in nucleotide repeat expansion disorders.

Authors:  C M Rodriguez; P K Todd
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

3.  Electrostatic Complementarity Drives Amyloid/Nucleic Acid Co-Assembly.

Authors:  Allisandra K Rha; Dibyendu Das; Olga Taran; Yonggang Ke; Anil K Mehta; David G Lynn
Journal:  Angew Chem Int Ed Engl       Date:  2019-11-14       Impact factor: 15.336

4.  Engineered protein disaggregases mitigate toxicity of aberrant prion-like fusion proteins underlying sarcoma.

Authors:  Jeremy J Ryan; Macy L Sprunger; Kayla Holthaus; James Shorter; Meredith E Jackrel
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

5.  ULK1 and ULK2 Regulate Stress Granule Disassembly Through Phosphorylation and Activation of VCP/p97.

Authors:  Bo Wang; Brian A Maxwell; Joung Hyuck Joo; Youngdae Gwon; James Messing; Ashutosh Mishra; Timothy I Shaw; Amber L Ward; Honghu Quan; Sadie Miki Sakurada; Shondra M Pruett-Miller; Tulio Bertorini; Peter Vogel; Hong Joo Kim; Junmin Peng; J Paul Taylor; Mondira Kundu
Journal:  Mol Cell       Date:  2019-04-09       Impact factor: 17.970

Review 6.  Spiraling in Control: Structures and Mechanisms of the Hsp104 Disaggregase.

Authors:  James Shorter; Daniel R Southworth
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-08-01       Impact factor: 10.005

7.  Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System.

Authors:  Yasunori Hayashi; Lenzie K Ford; Luana Fioriti; Leeanne McGurk; Mingjie Zhang
Journal:  J Neurosci       Date:  2021-01-20       Impact factor: 6.167

Review 8.  Generic nature of the condensed states of proteins.

Authors:  Monika Fuxreiter; Michele Vendruscolo
Journal:  Nat Cell Biol       Date:  2021-06-09       Impact factor: 28.824

9.  Phase Separation of Toxic Dipeptide Repeat Proteins Related to C9orf72 ALS/FTD.

Authors:  Hamidreza Jafarinia; Erik van der Giessen; Patrick R Onck
Journal:  Biophys J       Date:  2020-07-16       Impact factor: 4.033

Review 10.  The Pathophysiology of Tau and Stress Granules in Disease.

Authors:  Anna Cruz; Mamta Verma; Benjamin Wolozin
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.